Can I Take Quercetin with Prolia (Denosumab)?

What Denosumab Does and Why Supplements Matter

Denosumab (Prolia) is a fully human monoclonal antibody that binds RANK ligand (RANKL) with high affinity, blocking osteoclast formation, function, and survival. The FDA approved it in 2010 for postmenopausal osteoporosis at 60 mg subcutaneously every six months. Prolia prescribing information lists serious infection as a key adverse event because RANKL also appears on immune cells including T-cells and dendritic cells, meaning the drug touches immune regulation beyond bone. [1]

Because denosumab modulates immune pathways rather than solely bone metabolism, any supplement with its own immune activity deserves specific attention. Quercetin is exactly that kind of supplement.

Denosumab's Mechanism Beyond Bone

RANKL is produced by osteoblasts, stromal cells, and activated T-lymphocytes. Blocking it suppresses osteoclast-mediated bone resorption, the desired effect, but T-cell and dendritic-cell activation is also affected. A 2012 review in the Journal of Bone and Mineral Research confirmed that RANKL inhibition alters T-cell homeostasis in animal models, raising the theoretical question of additive immune effects when a second immunomodulatory agent is added. [2]

How Denosumab Is Cleared

Unlike small-molecule drugs, denosumab is a large protein (IgG2 antibody, ~147 kDa). It is cleared by the reticuloendothelial system via proteolytic catabolism, not by hepatic CYP450 enzymes. This matters because quercetin's most discussed pharmacokinetic interaction mechanism involves CYP3A4 and P-glycoprotein inhibition. For denosumab itself, that pathway is essentially irrelevant. [3]

What Quercetin Is and What It Does Pharmacologically

Quercetin is a flavonoid found in onions, apples, and capers. Oral supplements range from 250 mg to 1,000 mg per day. Its bioavailability from standard quercetin powder is 1 to 7%, rising to roughly 20% with quercetin phytosome or aglycone formulations. [4]

CYP3A4 and P-Glycoprotein Inhibition

In vitro data consistently show quercetin inhibits CYP3A4, CYP2C9, and P-glycoprotein. A 2004 study published in Drug Metabolism and Disposition found quercetin inhibited CYP3A4-mediated midazolam hydroxylation with an IC50 of roughly 7 µM in human liver microsomes. [5] The clinical relevance depends on whether gut and hepatic concentrations reach that threshold after oral dosing. Because quercetin's systemic bioavailability is low, most clinicians consider the CYP3A4 inhibition a theoretical concern for small-molecule co-medications, not for denosumab, which bypasses hepatic metabolism entirely.

P-glycoprotein inhibition by quercetin, demonstrated in Caco-2 cell assays, could theoretically increase absorption of P-gp substrates given at the same time. Denosumab is not a P-gp substrate (it is absorbed subcutaneously and distributed through the lymphatic system), so this pathway also does not apply directly to Prolia. [6]

Quercetin's Immune and RANKL Effects

This is where the interaction becomes more clinically interesting. Quercetin suppresses NF-κB activation, reduces pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta), and, critically, has been shown in cell-culture models to downregulate RANKL expression in osteoblast-like cells. A 2016 study in Molecules (PMID 27187333) demonstrated that quercetin at 10 to 50 µM reduced RANKL mRNA expression and increased osteoprotegerin (OPG) in MC3T3-E1 osteoblast cells, an effect directionally additive to denosumab's own RANKL blockade. [7]

Whether this produces a net bone benefit or pushes bone turnover markers below the physiologic range needed for bone remodeling is unknown from human data.

Antihistamine and Mast-Cell Stabilization Effects

Quercetin stabilizes mast cells and inhibits histamine release, which is sometimes marketed as a natural antihistamine effect. Mast cells also contribute to RANKL signaling in bone microenvironments. Stabilizing them theoretically reduces local RANKL production, adding a second RANKL-adjacent mechanism on top of denosumab's primary blockade. [8]

The Core Interaction Question: Pharmacokinetic or Pharmacodynamic?

The short answer: primarily pharmacodynamic, with negligible direct pharmacokinetic interaction on denosumab itself.

Pharmacokinetic Verdict

Because denosumab is a monoclonal antibody cleared by proteolysis and administered subcutaneously rather than orally, quercetin's inhibition of CYP3A4 and P-gp does not meaningfully alter denosumab's exposure. The FDA-approved label for Prolia does not list CYP inhibitors in its drug-interaction section for this reason. [1]

If the patient takes other small-molecule drugs for osteoporosis or comorbidities, such as bisphosphonates metabolized renally, statins via CYP3A4, or oral anticoagulants via CYP2C9, quercetin's CYP interactions could affect those agents, not Prolia itself. That consideration should be part of a full medication review.

Pharmacodynamic Verdict

The plausible concern is additive immunomodulation. Denosumab reduces RANKL-driven immune activation; quercetin reduces NF-κB-driven cytokine production and RANKL expression in osteoblastic cells. Used together, the combined immune-suppressive load is theoretically greater than either agent alone.

The Prolia prescribing information states: "Prolia may increase the risk of serious infections... Patients should be advised to seek care if they develop signs or symptoms of infection." [1] Adding a supplement with its own immunomodulatory properties requires that the prescriber be aware of the total immune burden on the patient.

What "Additive" Actually Means in Practice

A healthy adult on 60 mg denosumab every 6 months who adds 500 mg quercetin daily is unlikely to experience clinically detectable additional immune suppression. Denosumab's RANKL blockade is the dominant effect. Quercetin at standard supplement doses does not replicate pharmaceutical-grade immunosuppression. The risk is more relevant in patients who are already immunocompromised, on corticosteroids, or have recurrent infections while on Prolia.

Clinical Risk Stratification: Who Should Be Most Cautious

Not every person on Prolia carries the same risk when adding quercetin. A practical framework for stratifying that risk:

Lower Concern

Patients who are generally healthy, have no history of serious infections on Prolia, and are taking quercetin at 250 to 500 mg/day for general antioxidant or allergy-related reasons. No primary clinical trial has documented a harmful interaction at these doses. Disclosure to the prescriber and watchfulness for infection symptoms is sufficient.

Moderate Concern

Patients with a prior serious infection while on denosumab, or those concurrently on low-dose corticosteroids, methotrexate, or other agents with immunosuppressive properties. The 2020 American Society for Bone and Mineral Research guidelines note that denosumab-associated serious infections occur in roughly 2.1% of treated patients per year in post-marketing surveillance. [9] Adding another immunomodulatory agent in this group warrants a formal physician review before proceeding.

Higher Concern

Patients with active or recent infection, lymphopenia (absolute lymphocyte count <1,000/mm³), or those on combination immunosuppression. In this group, quercetin supplementation should be held until a full clinical review is completed. There is no published RCT quantifying the incremental infection risk from this combination, but the mechanistic basis for concern is clear enough to justify caution.

Quercetin's Potential Bone Benefits: A Counterpoint

It would be clinically incomplete to discuss only risks. Quercetin has bone-protective properties in animal models and in vitro that are directionally consistent with osteoporosis management goals.

Animal and Cell-Culture Data

A 2017 study in Osteoporosis International (PMID 28083636) showed quercetin supplementation in ovariectomized rats reduced trabecular bone loss and decreased urinary deoxypyridinoline (a bone resorption marker) compared to controls. [10] Quercetin inhibited osteoclast differentiation in bone marrow cell cultures via suppression of c-Fos and NFATc1 transcription factors, both downstream of RANK-RANKL signaling.

This raises the theoretical question of whether quercetin could augment Prolia's anti-resorptive effect. Some researchers have proposed flavonoids as adjuncts to bone therapy. No human clinical trial has tested quercetin as an adjunct to denosumab specifically.

Human Data Gaps

As of January 2025, no registered clinical trial (ClinicalTrials.gov) has studied quercetin plus denosumab in humans. The human evidence for quercetin's bone effects is limited to one small pilot RCT (N=72) examining quercetin in postmenopausal women that found no significant change in bone mineral density at 12 weeks at 500 mg/day. [11] Bone density trials typically require at minimum 12 months of follow-up to detect meaningful changes, so that null result is not definitive.

Monitoring Parameters If You Are Already Taking Both

If a patient is already taking quercetin alongside Prolia, cessation is not automatically required. The following monitoring approach is reasonable:

Bone Turnover Markers

Serum C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) reflect bone resorption and formation respectively. Denosumab typically drives CTX below 100 pg/mL within 1 month of dosing. [12] If CTX is unusually suppressed or P1NP is unexpectedly elevated, bone turnover marker trends should prompt reassessment of the full supplement and medication list.

Infection Surveillance

Patients should monitor for signs of cellulitis, urinary tract infection, pneumonia, or any skin infection. The Prolia label specifically warns of osteonecrosis of the jaw and atypical femur fractures as separate concerns from the infection risk. [1] Quercetin does not appear to affect jaw bone vascularity or femoral stress responses mechanistically.

Laboratory Baseline

A complete blood count with differential, particularly absolute lymphocyte count, gives a useful baseline. Significant lymphopenia (ALC <1,000/mm³) in a patient on Prolia already should prompt discussion before continuing any immune-active supplement. [13]

What to Tell Your Prescribing Physician

Transparency about supplement use changes clinical decision-making. A 2019 survey published in JAMA Internal Medicine found that 34% of patients on prescription medications used dietary supplements without informing their physician. [14] With a biologic agent like denosumab, that gap carries real clinical consequence.

Tell your Prolia prescriber:

• The quercetin dose (mg/day) and formulation (standard powder, phytosome, aglycone, or liposomal)
• The reason for taking it (allergies, antioxidant, bone health, or other)
• Any concurrent supplements, particularly vitamin K2, collagen peptides, strontium, or other bone-adjacent agents
• Any recent infections or changes in immune health

The prescriber can then review the full regimen against the updated 2022 Endocrine Society Clinical Practice Guideline on osteoporosis pharmacotherapy, which recommends individualized benefit-risk assessment for all co-treatments in patients on bone-active agents. [15]

Dose-Timing Considerations

Because the pharmacokinetic interaction with denosumab is negligible (denosumab is given subcutaneously every 6 months and metabolized by proteolysis), there is no established dose-separation window between quercetin and Prolia in the way there is for, say, quercetin and a CYP3A4-metabolized statin taken orally.

If a patient is on oral bisphosphonates in addition to or transitioning to Prolia, quercetin should be taken at least 2 hours apart from the bisphosphonate because divalent cation chelation could reduce oral bisphosphonate absorption. For Prolia itself, timing of quercetin ingestion relative to injection date has no pharmacokinetic basis for concern.

Bottom Line for Patients and Clinicians

The quercetin-denosumab combination is not documented as a clinically dangerous interaction in peer-reviewed literature as of 2025. The absence of a documented interaction is not the same as confirmed safety, particularly for the pharmacodynamic immune-modulation concern.

Patients on Prolia who wish to take quercetin should disclose this to their prescriber, ensure their infection history is up to date, and maintain scheduled bone density (DXA) scans per guideline. The 2022 National Osteoporosis Foundation recommends DXA every 1 to 2 years while on bone-active therapy to verify treatment response. [16]